Bibliography
- Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003;60:1119-22
- Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 2007;3:186-91
- Alzheimer's Association. Alzheimer's disease facts and figures. Alzheimers Dement 2011;7(2):208-44
- Bertram L, Tanzi RE. Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nat Rev Neurosci 2008;9:768-78
- Raber J, Huang Y, Ashford JW. ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol Aging 2004;25:641-50
- Jonsson T, Stefansson H, Steinberg S, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med 2012; In press
- Guerreiro R, Wojtas A, Bras J, et al. TREM2 variants in Alzheimer's disease. N Engl J Med 2012; In press
- Whitmer RA, Sidney S, Selby J, et al. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 2005;64:277-81
- Cechetto DF, Hachinski V, Whitehead SN. Vascular risk factors and Alzheimer's disease. Expert Rev Neurother 2008;8:743-50
- Xu WL, von Strauss E, Qiu CX, et al. Uncontrolled diabetes increases the risk of Alzheimer's disease: a population-based cohort study. Diabetologia 2009;52:1031-9
- Galbussera A, Tremolizzo L, Isella V, et al. Lack of evidence for Borrelia burgdorferi seropositivity in Alzheimer disease. Alzheimer Dis Assoc Disord 2008;22:308
- Johnson VE, Stewart W, Smith DH. Traumatic brain injury and amyloid-beta pathology: a link to Alzheimer's disease? Nat Rev Neurosci 2010;11:361-70
- Ring R, Lyons J. Failure to detect Chlamydophila pneumoniae in late onset Alzheimer's brain. J Clin Microbiol 2000;38:2591-4
- Holmes C, Cotterell D. Role of infection in the pathogenesis of Alzheimer's disease, implications for treatment. CNS Drugs 2009;23:993-1002
- Graves A, Van Duijn C, Chandra V, et al. Occupational exposures to solvents and lead as risk factors for Alzheimer's disease. Int J Epidemiol 1991;20(Suppl 2):S58-61
- Yaffe K. Antioxidants and prevention of cognitive decline: does duration of use matter? Arch Intern Med 2007;167:2167-8
- Kumar V, Kinsella L. Healthy brain aging: effect of head injury, alcohol and environmental toxins. Clin Geriatr Med 2010;26:29-44
- Matthews BR. Alzheimer disease update. Continuum (Minneap Minn) 2010;16(2 Dementia):15-30
- Vemuri P, Wiste H, Weigand S, et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology 2009;73:294-301
- Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:280-92
- Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992;256:184-5
- Selkoe D, Schenk D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 2003;43:545-84
- Greicius MD, Srivastava G, Reiss AL, Menon V. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci USA 2004;101:4637-42
- Furukawa K, Sopher B, Rydel R, et al. Increased activity-regulating and neuroprotective efficacy of alpha-secretase-derived secreted amyloid precursor protein conferred by a C-terminal heparin-binding domain. J Neurochem 1996;67:1882-96
- Gandy S, Martins R, Buxbaum J. Molecular and cellular basis for anti-amyloid therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 2003;17:259-66
- Rosenberg R. Translational research on the way to effective therapy for Alzheimer disease. Arch Gen Psychiatry 2005;62:1186-92
- Cummings J. Alzheimer's disease. N Engl J Med 2004;351:56-67
- Auld DS, Kornecook TJ, Bastianetto S, Quirion R. Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. Prog Neurobiol 2002;68:209-45
- Hynd MR, Scott HL, Dodd PR. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochem Int 2004;45:583-95
- Shah RS, Lee H-G, Xiongwei Z, et al. Current approaches in the treatment of Alzheimer's disease. Biomed Pharmacother 2008;62:199-207
- Hyman BT. Amyloid-dependent and amyloid-independent stages of Alzheimer disease. Arch Neurol 2011;68:1062-4
- Knopman DS. Mild cognitive impairment and on to dementia: down the slippery slope but faster. Neurology 2010;74:942-4
- Hoozemans J, Veerhuis R, Rozemuller J, Eikelenboom P. Neuroinflammation and regeneration in the early stages of Alzheimer's disease pathology. Int J Dev Neurosci 2006;24:157-65
- King ME, Kan HM, Baas PW, et al. Tau-dependent microtubule disassembly initiated by prefibrillar beta-amyloid. J Cell Biol 2006;175:541-6
- Beal MF. Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q as a potential treatment. J Bioenerg Biomembr 2004;36:381-6
- Beal MF. Mitochondria take center stage in aging and neurodegeneration. Ann Neurol 2005;58:495-505
- Carlson CM. Type 2 diabetes mellitus, dyslipidemia, and Alzheimer's disease. J Alzheimers Dis 2010;20:711-22
- Craft S. The role of insulin dysregulation in aging and Alzheimer's disease. In: Craft S, Christen Y, editors. Diabetes, insulin and Alzheimer's disease. Springer; Berlin Heidelberg: 2010. p. 109-27
- Luchsinger JA, Tang M-X, Shea S, Mayeux R. Antioxidant vitamin intake and risk of Alzheimer disease. Arch Neurol 2003;60:203-8
- Tayeb HO, Yang HD, Price BH, Tarazi FI. Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors. Pharmacol Ther 2012;134:8-25
- De Strooper B, Annaert W, Cupers P, et al. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature 1999;398:518-22
- Wong G, Manfra D, Poulet F, et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 2004;279:12876-82
- Clinicaltrials.gov. Effect of LY450139 on the long term progression of Alzheimer's disease [IDENTITY 1]. Clinicaltrials.gov identifier NCT-00594568
- Clinicaltrials.gov. Effects of LY450139, on the progression of Alzheimer's disease as compared with placebo [IDENTITY 2]. Clinicaltrials.gov identifier NCT-00762411
- Green RC, Schneider LS, Amato DA, et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 2009;302:2557-64
- Galasko D, Graff-Radford N, May S, et al. Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals. Alzheimer Dis Assoc Disord 2007;21:292-9
- Martone RL, Zhou H, Atchison K, et al. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease. J Pharmacol Exp Ther 2009;331:598-608
- Gervais F, Chalifour R, Garceau D, et al. Glycosaminoglycan mimetics: a therapeutic approach to cerebral amyloid angiopathy. Amyloid 2001;8(Suppl 1):28-35
- Aisen P, Gauthier S, Ferris S, et al. Tramiprosate in mild-to-moderate Alzheimer's disease—a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study). Arch Med Sci 2011;7:102-11
- Gilman S, Koller M, Black RS, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005;64:1553-62
- Orgogozo J, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003;61:46-54
- Nicoll JA, Wilkinson D, Holmes C, et al. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003;9:448-52
- Ferrer I, Rovira MB, Guerra MLS, et al. Neuropathology and pathogenesis of encephalitis following amyloid beta immunization in Alzheimer's disease. Brain Pathol 2004;14:11-20
- Maier M, Seabrook TJ, Lazo ND, et al. Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response. J Neurosci 2006;26:4717-28
- ClinicalTrials.Gov. Safety, tolerability and Abeta-specific antibody response of repeated i.m. injections of adjuvanted CAD106 in mild Alzheimer patients. ClinicalTrialsgov identifier: NCT01097096
- ClinicalTrials.Gov. To investigate the safety and tolerability of repeated subcutaneous injections of CAD106 in Alzheimer's patients. Clinicaltrialsgov identifier: NCT00956410
- Lombardo JA, Stern EA, McLellan ME, et al. Amyloid beta antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J Neurosci 2003;23:10879-83
- Brendza RP, Bacskai BJ, Cirrito JR, et al. Anti-A beta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J Clin Invest 2005;115:428-33
- Dodart J-C, Bales KR, Gannon KS, et al. Immunization reverses memory deficits without reducing Abeta burden in Alzheimer's disease model. Nat Neurosci 2002;5:452-7
- Walsh DM, Selkoe DJ. Abeta oligomers – a decade of discovery. J Neurochem 2007;101:1172-84
- Panza F, Frisardi V, Imbimbo BP, et al. Bapineuzumab: anti-beta-amyloid monoclonal antibodies for the treatment of Alzheimer's disease. Immunotherapy 2010;2:767-82
- Black RS, Sperling RA, Safirstein B, et al. A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 2010;24:198-203
- Panza F, Frisardi V, Imbimbo BP, et al. Monoclonal antibodies against -amyloid (A) for the treatment of Alzheimer's disease: the A target at a crossroads. Expert Opin Biol Ther 2011;11:679-86
- ClinicalTrials.Gov. A long-term safety and tolerability study of bapineuzumab in Alzheimer disease patients. ClinicalTrialsgov identifier: NCT00667810
- ClinicalTrials.Gov. A long-term safety and tolerability extension study of bapineuzumab in Alzheimer disease patients. Clinicaltrialsgov identifier: NCT00676143
- ClinicalTrials.Gov. Study evaluating the long-term safety and efficacy of subcutaneous Bapineuzumab. ClinicalTrialsgov identifier: NCT00916617
- Johnson and Johnson Press Release. Johnson and Johnson announces discontinuation of phase 3 development of Bapineuzumab intravenous (IV) in mild-to-moderate Alzheimer's disease. Press Release; August 6, 2012
- Salloway S, Sperling R, Gilman S, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009;73:2061-70
- Sperling RA, Jack CR Jr, Black SE, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement 2011;7:367-85
- Seubert P, Barbour R, Khan K, et al. Antibody capture of soluble A beta does not reduce cortical Abeta amyloidosis in the PDAPP mouse. Neurodegener Dis 2008;5:65-71
- DeMattos RB, Bales KR, Cummins DJ, et al. Peripheral anti-A beta antibody alters CNS and plasma Abeta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2001;98:8850-5
- DeMattos RB, Bales KR, Cummins DJ, et al. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 2002;295:2264-7
- Siemers E, Friedrich S, Dean R. Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol 2010;33:67-73
- Farlow M AS, van Dyck CH, Aisen PS, et al. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement 2012(8):261-71
- ClinicalTrials.Gov. Effect of LY2062430 on the progression of Alzheimer's disease (EXPEDITION 1). Clinicaltrialsgov identifier: NCT00905372
- ClinicalTrials.Gov. Effect of LY2062430 on the progression of Alzheimer's disease (EXPEDITION 2). Clinicaltrialsgov identifier: NCT00904683
- Samadi H, Sultzer D. Solanezumab for Alzheimer's disease. Expert Opin Biol Ther 2011;11:787-98
- ClinicalTrials.Gov. Continued safety monitoring of Solanezumab in Alzheimer's disease (EXPEDITION EXT). Clinicaltrialsgov identifier: NCT01127633
- Eli Lilly press release. Eli Lilly and Co. announces top-line results on solanezumab phase 3 clinical trials in patients with Alzheimer's Disease. Press release, October 8, 2012
- The Clinical Trials in Alzheimer's Disease (CTAD) press release. Independent analysis of solanezumab provides evidence that compound may remove amyloid from brain in Alzheimer's disease. Press release, October 29, 2012
- Lee HG, Casadesus G, Zhu X, et al. Challenging the amyloid cascade hypothesis: senile plaques and amyloid-beta as protective adaptations to Alzheimer's disease. Ann NY Acad Sci 2004;1019:1-4
- McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:263-9
- Reiman EM, Langbaum JB, Tariot PN. Alzheimer's prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible. Biomark Med 2010;4:3-14
- Banner Health Press Release. Groundbreaking Alzheimer's disease prevention trial announced. Press Release, May 15, 2012
- Morris JC, Aisen PS, Bateman RJ, et al. Developing an international network for Alzheimer research: the dominantly inherited Alzheimer network. Clin Investig 2012;2:975-84
- Washington University in St. Louis Press Release. Investigational drugs chosen for major Alzheimer's prevention trial. Press Release October 10, 2012
- Alzheimer's Association International Conference. New methods reported for safely and accurately disclosing Alzheimer's disease risk based on newly approved tests. AAIC Press Release, July 17, 2012